Literature DB >> 1322359

Familial amyloidosis, Finnish type: G654----a mutation of the gelsolin gene in Finnish families and an unrelated American family.

A de la Chapelle1, J Kere, G H Sack, R Tolvanen, C P Maury.   

Abstract

The Finnish type of familial amyloid polyneuropathy (FAF) is an autosomal dominant form of systemic amyloidosis caused by a mutation in the gelsolin gene. The mutation leads to the expression of amyloidogenic mutant Asp187----Asn gelsolin, an actin-modulating protein. We previously developed a DNA test based on amplification by the polymerase chain reaction followed by allele-specific oligonucleotide hybridization that identifies the base substitution adenine for guanine at nucleotide 654 in the gelsolin gene causing the disease. We show here that the same mutation is present in members of six apparently unrelated Finnish families and in a member of an unrelated American family. These results, taken together with previously published findings in nine additional Finnish families and another unrelated American family, indicate that most, perhaps all, FAF patients in Finland and possibly worldwide carry the same mutation. We suggest two alternative explanations: (i) the mutation arose in a very early common ancestor or (ii) the Asn187 mutation is particularly, perhaps uniquely, amyloidogenic.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322359     DOI: 10.1016/0888-7543(92)90182-r

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  13 in total

1.  Accelerators, Brakes, and Gears of Actin Dynamics in Dendritic Spines.

Authors:  Crystal G Pontrello; Iryna M Ethell
Journal:  Open Neurosci J       Date:  2009-01-01

2.  Clinical features and haplotype analysis of newly identified Japanese patients with gelsolin-related familial amyloidosis of Finnish type.

Authors:  Makiko Taira; Hiroyuki Ishiura; Jun Mitsui; Yuji Takahashi; Toshihiro Hayashi; Jun Shimizu; Takashi Matsukawa; Naoko Saito; Kazumasa Okada; Sadatoshi Tsuji; Hiromasa Sawamura; Shiro Amano; Jun Goto; Shoji Tsuji
Journal:  Neurogenetics       Date:  2012-05-24       Impact factor: 2.660

Review 3.  Disease gene mapping in isolated human populations: the example of Finland.

Authors:  A de la Chapelle
Journal:  J Med Genet       Date:  1993-10       Impact factor: 6.318

4.  Danish type gelsolin related amyloidosis: 654G-T mutation is associated with a disease pathogenetically and clinically similar to that caused by the 654G-A mutation (familial amyloidosis of the Finnish type).

Authors:  C P Maury; M Liljeström; G Boysen; T Törnroth; A de la Chapelle; E L Nurmiaho-Lassila
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

5.  Two mutations in the transforming growth factor beta-induced gene associated with familial Lattice corneal dystrophy.

Authors:  Wen-Ping Cao; Hai-Gang Yuan; Ping Liu; Xue Li; Qi Hu
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

6.  TGFBI, CHST6, and GSN gene analysis in Mexican patients with stromal corneal dystrophies.

Authors:  Johanna Gonzalez-Rodriguez; Arturo Ramirez-Miranda; Sergio E Hernandez-Da Mota; Juan C Zenteno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-07       Impact factor: 3.117

7.  Immunohistochemical analysis of lattice corneal dystrophies types I and II.

Authors:  T Kivelä; A Tarkkanen; I McLean; J Ghiso; B Frangione; M Haltia
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

8.  Asp187Asn mutation of gelsolin in an American kindred with familial amyloidosis, Finnish type (FAP IV).

Authors:  R D Steiner; T Paunio; T Uemichi; J P Evans; M D Benson
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

9.  The First Korean Family With Hereditary Gelsolin Amyloidosis Caused by p.D214Y Mutation in the GSN Gene.

Authors:  Kyoung Jin Park; Jong Ho Park; June Hee Park; Eun Bin Cho; Byoung Joon Kim; Jong Won Kim
Journal:  Ann Lab Med       Date:  2016-05       Impact factor: 3.464

10.  Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study.

Authors:  Eeva-Kaisa Schmidt; Tuuli Mustonen; Sari Kiuru-Enari; Tero T Kivelä; Sari Atula
Journal:  Orphanet J Rare Dis       Date:  2020-01-17       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.